However, combination treatment with a USP7 inhibitor and PLK1 inhibitor exerts a strong synergistic effect in lung cancer cells resistant to paclitaxel, suggesting that co-targeting USP7 and PLK1 may be a valuable strategy for future clinical translation research. Here, USP7 is linked to lung carcinoma.